Lead Prodrug Candidate

About Brimstalt Therapeutics

Brimstalt Therapeutics is a private, preclinical oncology company pioneering a tumor-activated prodrug platform. Its lead candidate is designed to be activated by a specific tumor-associated enzyme (TAE) overexpressed in 5-15% of patients across various cancer types, enabling a tissue-agnostic, targeted chemotherapy approach. The company operates with a capital-efficient model as a portfolio company of Fannin Innovation and is advancing its lead compound, which has shown significant tumor reduction in mouse models, toward clinical development. Brimstalt aims to establish new standards of care for patients who have failed standard treatments.

Therapeutic Areas